written on 02.03.2014

BioNotebook: Medivation, Clovis, Arena 4Q updates; Abide/Celgene discovery deal; 3 new IPO filers, 2 other set terms


The Nasdaq index closed down just 0.25%, but the Nasdaq Biotechnology Index (NBI) closed down 2.8%. Medivation ended the day 14.9% lower at $71.91 based on the company's conservative revenue forecast for 2014 Xtandi (enzalutamide) sales. The company lost…